CTOs on the Move

Kyverna Therapeutics

www.kyvernatx.com

 
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases. Our therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of disease. Kyverna is venture-backed and located in the San Francisco East Bay.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Karen Walker
Chief Technology Officer Profile

Funding

Kyverna Therapeutics raised $25M on 01/13/2020

Similar Companies

Quintiles

Quintiles is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

C16 Biosciences

C16 was founded with the objective of creating a sustainable, environmentally friendly alternative to conflict palm oil. By offering producers, refiners, traders and consumers of palm oil an opportunity to invest part of their production into bio-based oils and sustainability efforts, our aim is to reduce the environmental footprint of palm oil production and protect precious natural land, wildlife and resources in the process.

Lumen Bioscience

Lumen Bioscience develops oral antibody therapeutics.

Miltenyi Biotec

We`re committed to helping researchers and clinicians make a greater impact on science and health. For more than 25 years, our work has played an essential role in the cell research and cell therapy community. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our integrated technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. This complete portfolio enables the access, analysis, and utilization of primary and primary-derived cells. Our expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. Today, Miltenyi Biotec has more than 2,000 employees in 25 countries.

Olink Proteomics

Thoroughly validated, rapid, high-throughput multiplexed assays for protein biomarker discovery - high specificity & minimal sample volume requirements